Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eli Lilly and Company (NYSE: LLY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand Lilly’s capital structure, governance, financing activities and material events affecting the business.
Lilly’s common stock and several series of notes are registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the New York Stock Exchange, including common stock under the symbol LLY and multiple note series with maturities ranging from 2026 to 2061. Recent Form 8-K filings disclose items such as quarterly financial results furnished under Item 2.02, other events under Item 8.01, and governance changes under Item 5.02. For example, an August 2025 Form 8-K describes an underwriting agreement for floating-rate notes due 2028 and fixed-rate notes due between 2028 and 2065, while a November 2025 Form 8-K reports the election of a new independent director to Lilly’s board.
Through this page, users can review current and historical 8-Ks, along with other core filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q when available. These filings typically include details on Lilly’s therapeutic focus areas—such as cardiometabolic health, obesity, oncology, immunology and neuroscience—its risk factors, research and development programs, and financial condition.
Stock Titan enhances access to Lilly’s filings by pairing real-time EDGAR updates with AI-powered summaries. AI-generated overviews can help explain the significance of complex documents, such as new debt offerings, governance changes or major transactions, in plain language. Users can also quickly identify insider and executive-related disclosures when they appear in Forms 3, 4 or 5, and track how financing decisions, such as multi-series note issuances, fit into Lilly’s broader capital strategy.
Whether you are analyzing LLY’s latest 10-K, reviewing 10-Q trends, or examining 8-Ks related to acquisitions, collaborations and manufacturing investments, this filings hub offers a structured view of the company’s regulatory record with tools to make dense disclosures easier to interpret.
Lilly Endowment Inc., a more than 10% owner of Eli Lilly & Co. (LLY), reported a sale of company stock. On 01/05/2026, the reporting person sold 1,390 shares of Eli Lilly common stock at a weighted average price of $1,085.011 per share. The sale was executed in multiple trades at prices ranging from $1,085.00 to $1,085.10.
Following this transaction, the reporting person beneficially owned 92,189,126 shares of Eli Lilly common stock in direct ownership. The filing notes that detailed trade-by-trade pricing information within the reported range will be provided upon request. The form was signed by Diane M. Stenson, Vice President and Treasurer, on behalf of Lilly Endowment Inc.
Eli Lilly & Co reported an insider transaction by a director-level reporting person. On 12/29/2025, the reporting person sold 3,593 shares of Eli Lilly common stock in an open-market transaction coded "S".
The weighted average sale price was $1,085.035 per share, with individual trades executed between $1,085.00 and $1,085.245. After this sale, the reporting person directly beneficially owned 92,190,516 Eli Lilly shares.
ELI LILLY & Co reported an insider transaction involving its stock. On 12/24/2025, the reporting person sold 2,629 shares of Eli Lilly common stock, listed with transaction code "S". The weighted average sale price was $1,085.173 per share, with individual trades executed between $1,085.00 and $1,085.53.
After this sale, the reporting person beneficially owned 92,194,109 shares of Eli Lilly common stock, held in direct ownership. The footnote explains that detailed trade information within the price range is available upon request from Eli Lilly & Company, its security holders, or the SEC staff.
Lilly Endowment Inc., a director and more than 10% owner of Eli Lilly & Co., reported a small open-market sale of company stock. On 12/23/2025, the reporting person sold 240 shares of common stock, coded as a sale transaction, at a weighted average price of $1,085.038 per share.
The shares were sold in multiple trades at prices ranging from $1,085.00 to $1,085.08. After this transaction, the reporting person beneficially owned 92,196,738 shares of Eli Lilly common stock in direct ownership form. The filer has undertaken to provide detailed trade breakdowns upon request to the company, its security holders, or the SEC staff.
Lilly Endowment Inc. has filed a notice of proposed sale under Rule 144 to sell 300,000 shares of Eli Lilly and Company common stock through Fidelity Capital Markets. The filing reports an aggregate market value of 322,944,000 for these shares, with an approximate sale date of 12/23/2025 and 945,383,757 Eli Lilly shares outstanding.
The notice also lists prior sales of Eli Lilly common stock by Lilly Endowment over the past three months, including 300,000 shares sold on 11/03/2025 for gross proceeds of 266,648,940 and several other large transactions in late September, October, and November 2025. By signing, the seller represents that it is not aware of any material adverse, nonpublic information about Eli Lilly’s operations.
Eli Lilly director Gabrielle Sulzberger reported acquiring 4.668 shares of the company’s common stock on 12/15/2025 at $1,062.19 per share in an insider transaction. Following this transaction, she beneficially owns 2,956.674 shares directly.
The shares were acquired by deferring cash compensation into stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock after her separation from service.
Eli Lilly & Co director Juan R. Luciano reported acquiring 13.965 shares of common stock on 12/15/2025 in a transaction coded “A” for acquisition at a price of $1,062.19 per share. After this transaction, he beneficially owned 16,741.37 shares held directly.
The shares acquired have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following Luciano’s separation from service with the company.
Eli Lilly & Co director Mary Lynne Hedley reported acquiring 9.336 shares of Eli Lilly common stock on 12/15/2025 at a price of $1,062.19 per share. According to the filing, at her election these shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following her separation from service.
After this transaction, she beneficially owned 2,252.694 shares of Eli Lilly common stock directly and 98 shares indirectly through a trust, for which she disclaims beneficial ownership except to the extent of her pecuniary interest.
Eli Lilly and Company director J. Erik Fyrwald elected to receive 9.336 stock units tied to Eli Lilly common stock on 12/15/2025 instead of cash compensation. The units were valued at $1,062.19 each under the Lilly Directors' Deferral Plan and will be settled in shares of common stock after his separation from service.
After this transaction, Fyrwald beneficially owns 75,101.227 shares of Eli Lilly common stock in direct holdings.
Eli Lilly & Co. director Ralph Alvarez reported acquiring 11.062 shares of Eli Lilly common stock on 12/15/2025 at a price of $1,062.19 per share. According to the filing, these shares were credited as stock units under the Lilly Directors' Deferral Plan in lieu of cash compensation and will be settled in shares of common stock after he separates from service as a director.
After this transaction, Alvarez beneficially owned 55,467.718 shares of Eli Lilly common stock directly and 758 shares indirectly through a trust, with the indirect ownership reported only to the extent of his pecuniary interest.